Patents by Inventor Kenneth Draper

Kenneth Draper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication
    Publication number: 20040127446
    Abstract: The present invention relates to nucleic acid molecules, including antisense and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes, Inozymes, Zinzymes, Amberzymes, and G-cleaver ribozymes, which modulate the synthesis, expression and/or stability of an HCV or HBV RNA and methods for their use alone or in combination with other therapies. In addition, nucleic acid decoy molecules and aptamers that bind to HBV reverse transcriptase and/or HBV reverse transcriptase primer sequences and methods for their use alone or in combination with other therapies, are disclosed. Oligonucleotides that specifically bind the Enhancer I region of HBV DNA are further disclosed. The present invention further relates to the use of nucleic acids, such as decoy and aptamer molecules of the invention, to modulate the expression of Hepatitis B virus (HBV) genes and HBV viral replication.
    Type: Application
    Filed: September 23, 2003
    Publication date: July 1, 2004
    Inventors: Lawrence Blatt, Dennis Macejak, James McSwiggen, David Morrissey, Pamela Pavco, Patrice Lee, Kenneth Draper, Elisabeth Roberts
  • Method and reagent for inhibiting hepatitis B viral replication
    Publication number: 20040054156
    Abstract: The present invention relates to nucleic acid molecules, including antisense and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes, Inozymes, Zinzymes, Amberzymes, and G-cleaver ribozymes, which modulate the synthesis, expression and/or stability of an RNA encoding one or more protein components of Hepatitis B virus (HBV), and methods for their use alone or in combination with other therapies, such as 3TC® (Lamivudine) and Interferons are disclosed.
    Type: Application
    Filed: January 15, 2003
    Publication date: March 18, 2004
    Inventors: Kenneth Draper, Lawrence Blatt, James A. McSwiggen, David Morrissey
  • Method and reagent for inhibiting hepatitis B virus replication
    Publication number: 20030068301
    Abstract: Nucleic acid molecules, including antisense and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes, Inozymes, Zinzymes, Amberzymes, and G-cleaver ribozymes, which modulate the synthesis, expression and/or stability of an RNA encoding one or more protein components of Hepatitis B virus (HBV), and methods for their use alone or in combination with other therapies, such as 3TC® (Lamivudine) and Interferons are disclosed.
    Type: Application
    Filed: June 8, 2001
    Publication date: April 10, 2003
    Inventors: Kenneth Draper, Lawrence Blatt, James A. McSwiggen, David Morrissey
  • C-myb ribozymes having 2'-5'-linked adenylate residues
    Patent number: 5817796
    Abstract: Enzymatic nucleic acid molecules which cleave c-myb RNA or other RNAs associated with restenosis or cancer.
    Type: Grant
    Filed: May 5, 1995
    Date of Patent: October 6, 1998
    Inventors: Dan T. Stinchcomb, Kenneth Draper, James McSwiggen, Thale Jarvis
  • TNF-.alpha. ribozymes
    Patent number: 5811300
    Abstract: Enzymatic RNA molecules which cleave TNF-.alpha. mRNA.
    Type: Grant
    Filed: September 23, 1994
    Date of Patent: September 22, 1998
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Sean Sullivan, Kenneth Draper, Kevin Kisich, Dan T. Stinchcomb, James McSwiggen
  • Respiratory syncytial virus ribozymes
    Patent number: 5693532
    Abstract: An enzymatic RNA molecule which cleaves respiratory syncytial virus (RSV) genomic and RSV encoded RNA.
    Type: Grant
    Filed: November 4, 1994
    Date of Patent: December 2, 1997
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: James McSwiggen, Kenneth Draper, Pam Pavco, Tod Woolf
  • C-myb targeted ribozymes
    Patent number: 5646042
    Abstract: Enzymatic nucleic acid molecules which cleave c-myb RNA or other RNAs associated with restenosis or cancer.
    Type: Grant
    Filed: January 13, 1995
    Date of Patent: July 8, 1997
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Dan T. Stinchcomb, Kenneth Draper, James McSwiggen, Thale Jarvis
  • Oligonucleotides for modulating the effects of cytomegalovirus infections
    Patent number: 5442049
    Abstract: Compositions and methods for modulating the effects of cytomegalovirus (CMV) infections are disclosed, comprising contacting CMV mRNA with an oligonucleotide which can bind with at least portions of the CMV RNA. In accordance with the preferred embodiments, oligonucleotides such as ISIS 2922 are designed to bind with portions of the CMV mRNAs which code for the IE1, IE2 or DNA polymerase proteins. In accordance with a preferred embodiment, methods of treatment of human cytomegalovirus are disclosed.
    Type: Grant
    Filed: January 25, 1993
    Date of Patent: August 15, 1995
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Kevin Anderson, Kenneth Draper, Brenda Baker